Propanc Biopharma (PPCB) revenue and earnings history
Propanc Biopharma's annual figures for 18 fiscal years, as filed with the SEC.
Revenue and net income, 18 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026ended Jun 30, 2026 | — | −$18.2M | −$18.9M | −$5.68M | $4.9K | −$5.69M | $8.5M | — | — | — | — | 10-K |
| 2025ended Jun 30, 2025 | — |
The latest quarter, insider trades and fund moves: Propanc Biopharma (PPCB) on OQRO.
Common questions
Has Propanc Biopharma been profitable?
It reported a net loss in 18 of the years shown (2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026). The highest net income was −$444K in fiscal 2009.
What was Propanc Biopharma's free cash flow in fiscal 2026?
−$5.69M: operating cash flow of −$5.68M minus capital expenditure of $4.9K. OQRO calculates free cash flow this way from the two filed lines.
Does Propanc Biopharma buy back shares or pay dividends?
None of the 18 annual reports shown tags a share buyback or a dividend payment in the standard US taxonomy.
Where these figures come from
The SEC’s companyfacts data: every figure Propanc Biopharma tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
